

Listing of Claims:

1. (Currently Amended) Matrix-controlled transdermal therapeutic system comprising (i) an active-ingredient-impermeable cover layer, (ii) a self-adhesive matrix layer, or a plurality of matrix layers of which at least the matrix layer exposed while applying the system is self-adhesive, or one or more matrix layers whose surface remote from the cover layer and intended for adhesion at the application site is coated with an adhesive, the matrix layer(s) comprising at least one ACE inhibitor (angiotensin converting enzyme inhibitor) selected from the group consisting of imidapril, fosinopril, moexipril, perindopril, ramipril, spirapril, cilazapril, benazepril and trandolapril, wherein the inhibitor is in the form of (a) a dicarboxylic acid which is derivatised to form a diester, or ~~(b) a mono salt formed with acid(s)~~; and (iii) a removable protective layer.
2. (Cancelled)
3. (Currently Amended) The system according to claim 1, characterised by at least one ACE inhibitor selected from the group consisting of imidapril, fosinopril, moexipril, perindopril, ramipril, spirapril, cilazapril and trandolapril, wherein the inhibitor is in the form of (a) a dicarboxylic acid which is derivatised to form a diester, or ~~(b) a mono salt formed with acid(s)~~.
4. (Cancelled)
5. (Previously Presented) The system according to claim 1 characterised by an ethyl ester of trandolapril and/or ramipril.

6. (Currently Amended) The system according to claim 1 characterised in that the ACE inhibitor carries, in addition to a first ester group, a further ester group from the following group: methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, pentyl, hexyl, heptyl, octyl, nonane, decane groups and isomers thereof; the first ester group being freely selected, the ACE inhibitor being a pharmaceutically acceptable compound, or the first and second ester group being identical.

7. (Previously Presented) The system according to claim 6, characterised in that the further ester group is an ethyl group.

8.-12. (Canceled)

13. (Previously Presented) The system according to claim 1, characterised by a content of ACE inhibitor(s) of from 2 to 25% by weight based on the matrix weight.

14. (Previously Presented) The system according to claim 1, characterised in that the system has, on that side of the cover layer which is remote from the matrix layer(s), a covering (overtape)

- (i) which extends beyond the cover layer on all sides and which is provided with an adhesive that covers its surface or at least the region, in itself uninterrupted, extending beyond the cover layer, or
- (ii) which covers over the surface of the cover layer but does not extend beyond it and which is provided with an adhesive that covers its surface.

15. (Previously Presented) The system according to claim 14, characterised in that the covering (overtape) provided with an adhesive completely covers over the active-ingredient-impermeable cover layer or is provided with one or more perforations above the cover layer or is of annular shape.

16. (Previously Presented) The system according to claim 14, characterised in that the active-ingredient-impermeable cover layer and the covering provided with an adhesive are permeable to water vapour.
17. (Previously Presented) The system according to claim 14, characterised in that the active-ingredient-impermeable cover layer and the covering (overtape) provided with an adhesive are made from the same material.
18. (Previously Presented) The system according to claim 14, characterised in that the matrix layer(s) comprise(s) one or more permeation enhancers.
19. (Previously Presented) The system according to claim 18, characterised by highly disperse silicon dioxide, polyoxyethylene 7-glycerol monocoate and/or 2-octyldodecanol (Eutanol G) as permeation enhancer(s).
20. (Cancelled)
21. (Previously Presented) The system according to claim 13, characterized by a content of ACE inhibitor(s) of from 10 to 15% by weight based on the matrix weight.